Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

Alphabet Stock holds above $400 as overbought signals warn of a pause

Alphabet Stock extends its climb with the primary uptrend...

Apple Stock Stalls Below $300 as Hourly Momentum Cools

Apple Stock remains in a firm daily uptrend just...

Stellantis Stock steadies at $7.84 as BofA cuts it to Underperform

Stellantis Stock stabilizes near its daily pivot as short-term...

SK Telecom Stock Pauses Near Resistance as Uptrend Holds

SK Telecom Stock (SKM) remains in a primary uptrend...

Mara Holdings Stock Turns Bullish, but 13.6–13.8 Resistance Looms

Mara Holdings Stock is tilting bullish on the daily...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.